20
2019-08
mTOR Inhibitor Developed by Suzhou Kintor Obtained Approval for Clinical Trials in China
[Suzhou, August 20, 2019] National Medical Products Administration officially granted a clinical trial approval to Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") on commencement of clinical trials of the drug (GT0486) as an mTOR inhibitor. The drug (GT0486) is a novel mTORC1 / mTORC2 inhibitor (the second generation of mTOR inhibitor) which is indicated for advanced solid tumors. Currently, there is no second generation of mTOR inhibitors on the market in China, and there are huge unmet clinical needs in the research area.
19
2019-08
[Suzhou, August 19, 2019]Suzhou Kintor Pharmaceuticals, Inc. (“Suzhou Kintor") and CMAB Biopharma (Suzhou) Inc. ("CMAB") announced together a comprehensive strategic cooperation agreement on the development and production of ALK-1 monoclonal antibody in Suzhou Biopharma Industrial Park (BioBAY).
21
2019-06
Suzhou Kintor Won "Extraordinary Biopharmaceutical Enterprise Award" of China Financing in 2019
[June 21, 2019, Hong Kong, China] The awarding ceremony of the "2019 China Financing Awards" sponsored by "China Financing", a high-end financial magazine on Hong Kong capital market, was successfully held in Hong Kong. Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor"), together with nine pharmaceutical enterprises such as WuXi Biologics, Henlius, CanSinoBio, Innovent Biologics and Hua Medicine, won "Extraordinary Biopharmaceutical Enterprise Award" of China Financing in 2019. Dr. Youzhi Tong, Chairman and Chief Executive Officer of Suzhou Kintor , was invited to attend the ceremony and accept the award on behalf of the company.
08
2018-05
Proxalutamide Tablet Phase III Clinical Trials Investigator Meeting Was Held Successfully
On May 6, 2018, Proxalutamide Tablet Phase III Clinical Trials Investigator Meeting attracting participation of more than 30 hospitals was successfully held at Hyatt Hotel in Suzhou, symbolizing the official start of the first phase III clinical trials of Suzhou Kintor.
24
2018-01
(January 24, 2018, Suzhou) Suzhou Kintor Pharmaceuticals, Inc. (hereinafter referred to as "Suzhou Kintor") and Pfizer Inc. (“Pfizer”) held a press conference on the development project of innovative antibody drug for cancer in Suzhou today. Under the agreement, Pfizer will grant Suzhou Kintor the exclusive license to develop, produce and commercialize an innovative antibody drug for cancer globally. This is the first time that Pfizer has authorized the license to develop innovative antibody drug to a local Chinese enterprise. The drug is also expected to become the world's first fully human therapeutic monoclonal antibody against Activin receptor-like kinase-1 (ALK-1) target.
11
2018-01
On January 11, 2018, Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") announced the completion of Series C investment of RMB 288 million. This round of investment was led by Green Pine Capital Partnership, and followed by Orient Securities Capital Investment, Hangzhou Betta Capital, CCB Investment, and Shanghai Broad Resources, etc.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn